SARS-CoV-2-Induced Pancreatitis is a Rare but Real Entity

Inamdar, Sumant; Trindade, Arvind J.

doi:10.1016/j.cgh.2021.05.020

Cited by 2 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While the underlying mechanisms require further investigation, data from this study highlights the clinically important association between COVID-19 and increased pancreatic enzymes. The worse outcome of COVID-19 patients in whom pancreatic enzyme >3 Â ULN supported the view of Inamdar et al [39], who divided patients with concomitant COVID-19 and increased pancreatic enzymes into 3 groups: (1) patients with serum lipase and/or amylase of <3 Â ULN, (2) patients with serum lipase and/or amylase of >3 Â ULN, but do not meet the Atlanta criteria for acute pancreatitis, and (3) patients with acute pancreatitis meeting the Atlanta criteria.…”

Section: Discussionsupporting

confidence: 70%

Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis

Yang

Dong

et al. 2022

Pancreatology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 70%

Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis

Yang

Dong

et al. 2022

Pancreatology

View full text Add to dashboard Cite

“…Гиперлипаземия при COVID-19, не соответствующая определению панкреатита, вероятно, вызвана критическим состоянием. Американские исследователи [60] выделяют три группы пациентов с COVID-19, у которых может быть повышенный уровень липазы: 1) пациенты в критическом состоянии, у которых уровень липазы ниже трех ВПН; 2) пациенты в критическом состоянии, у которых уровень липазы выше трех ВПН, но не соответствует Атлантским критериям панкреатита; 3) пациенты с панкреатитом, соответствующие Атлантским критериям (с известной этиологией панкреатита, а также идиопатическим панкреатитом, который может быть вызван инфекцией COVID-19).…”

Section: гиперферментемия при Covid-19unclassified

Pathology of exocrine part of pancreas in new coronavirus infection COVID-19

Трухан

Degovtsov

2022

Medicinskij alfavit

View full text Add to dashboard Cite

The initial stage of infection is the penetration of SARS-CoV-2 into target cells that have receptors for angiotensin-converting enzyme type II (ACE2). Levels of ACE2 receptors in exocrine and islet cells of the pancreas are higher than in the lungs, suggesting the potential for SARS-CoV-2 infection to cause pancreatic injury, and most notably the development of acute pancreatitis. It has been established that SARS-CoV-2 can infect exocrine and endocrine cells of the pancreas ex vivo and in vivo. In the electronic search engines PubMed and Scopus, we searched for literature on the association of a new coronavirus infection COVID-19 with pancreatic pathology, with an emphasis on ‘SARS-CoV-2’ or ‘COVID-19’ and ‘pancreas’ and ‘pancreatitis’. The sources found indicate that direct, indirect and systemic mechanisms of damage to the pancreas in COVID-19 are possible. The review considers the prevalence of acute pancreatitis in COVID-19, features of diagnosis, clinic and prognosis. Special attention is paid to hyperenzymemia observed in COVID-19. The conclusion notes that there is fairly strong evidence for an association between acute pancreatitis and COVID-19, but the diagnosis of acute pancreatitis associated with COVID-19 is challenging as other potential etiological factors must be ruled out

show abstract

SARS-CoV-2-Induced Pancreatitis is a Rare but Real Entity

Cited by 2 publications

References 4 publications

Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis

Prevalence and prognosis of increased pancreatic enzymes in patients with COVID-19: A systematic review and meta-analysis

Pathology of exocrine part of pancreas in new coronavirus infection COVID-19

Contact Info

Product

Resources

About